Rapid European Adoption of IntraLase(R) FS Laser Continues with First Placement in Scandinavia, Additional Installations in Germany

IntraLase Corp. (Nasdaq:ILSE) today announced that Dr. Jorn S.Jorgensen, founder, chief executive officer, and medical director ofEuroEyes, one of Germany's largest refractive surgery centers, haspurchased an IntraLase FS laser for his Copenhagen, Denmark, center.This purchase marks the first time the IntraLase technology forcreating the corneal flap, which is the initial step in all LASIKsurgery, will be available to patients in Scandinavia. Currently, hisEuroEyes centers in Hamburg, Stuttgart and Berlin are equipped withthe IntraLase technology. The addition of the IntraLase laser inDenmark establishes Dr. Jorgensen as the first European surgeon topurchase 4 lasers, and Dr. Jorgensen plans to install the IntraLase FSin all of his remaining centers in Germany.

The IntraLase FS technology brings computer-controlled precision,as well as superior safety and efficacy to the corneal flap procedure.The IntraLase system is rapidly replacing the hand-held microkeratomemetal blade worldwide as the preferred technology for performing thefirst step of LASIK surgery.

Commenting on his decision to equip all EuroEyes centers with theIntraLase technology, Dr. Jorgensen said, "I have been using theIntraLase FS laser since September 2004, and have experiencedfirst-hand the benefits of this technology, which deliversunparalleled safety, precision and predictability when creating theflap. Additionally, I have noted that my patients have superior visualoutcomes, faster visual recovery, and improved quality of visioncompared to procedures that use the blade. Word of these superioroutcomes is spreading, which has generated more business for mypractices."

Dr. Jorgensen is considered one of the pioneers of refractivesurgery in Germany. He opened his first refractive surgery center in1994 and has personally performed more than 35,000 LASIK procedures.Dr. Jorgensen is president of the VSDAR, a society of refractivesurgeons in Germany.

Robert J. Palmisano, president and chief executive officer ofIntraLase, said, "Our laser system is rapidly gaining traction inEurope because of our strategy to target surgeons like Dr. Jorgensenwho are innovators that quickly embrace breakthrough technology andinfluence others to follow. We are thrilled to have Dr. Jorgensen as astrong advocate of our technology and are pleased that he willchampion the IntraLase system in Scandinavia."

IntraLase was commercialized in the United States late in 2001 andreceived CE mark in March 2004. As of March 31, 2005, 254 lasers wereinstalled in ophthalmic practices worldwide and to date the companyhas sold more than 400,000 procedures around the globe. Currently,IntraLase lasers are installed throughout the United States and 20other countries.

Multiple clinical studies show the IntraLase laser provides forbetter vision by creating an optimal corneal surface under the flap,allowing for more precise vision correction. As a result, morepatients achieved vision better than 20/15 and even 20/12.5 when theIntraLase laser was used in the first step.

Data also supports that the IntraLase FS laser is making everyLASIK procedure safer, virtually eliminating the severe,sight-threatening complications sometimes caused by the hand-heldblade. Clinical studies report that the IntraLase FS laser issignificantly less likely to produce overly thin flaps or extremelythick flaps, events that could lead to serious complications.

About IntraLase Corp.:

IntraLase designs, develops and manufactures an ultra-fast laser,related software and disposable devices used to create a corneal flap,the first step in LASIK surgery for the correction of vision. Thecompany's products improve the safety, precision and visual results ofLASIK procedures by providing a computer-controlled laser solution inplace of the hand-held mechanical, metal-bladed microkeratometraditionally used to create corneal flaps. IntraLase lasers are alsoused in surgical approaches to the treatment of diseased corneas. Thecompany's lasers and disposable per procedure patient interfaces arepresently installed throughout the United States and 20 othercountries. IntraLase is headquartered and manufactures its products inIrvine, Calif. For additional information, visit the company's website: www.intralase.com.

Forward Looking Statements:

Statements contained in this press release that are not historicalinformation are forward-looking statements as defined within thePrivate Securities Litigation Reform Act of 1995. Forward-lookingstatements can be identified by the use of words such as "believe,""expect," "anticipate," "intend," "plan," "estimate," "project," orwords of similar meaning, or future or conditional verbs such as"will," "would," "should," "could," or "may." Such forward-lookingstatements are subject to risks and uncertainties that could causeactual results to differ materially from those projected or implied.Those risks and uncertainties include, but are not limited to: thedegree of continued acceptance of LASIK surgery; potentialcomplications revealed by long term follow up; the extent of adoptionof our product offering by LASIK surgeons; general economicconditions; changes in federal tax laws governing the ability ofpotential LASIK patients to use pre-tax dollars to pay for LASIKsurgery; the scope of government regulation applicable to ourproducts; patients' willingness to pay for LASIK surgery; our abilityto compete against our competitors; the effectiveness of our measuresto ensure full payment of procedure fees; the occurrence and outcomeof product liability suits against us; our ability to adequatelyprotect our intellectual property; whether we become subject to claimsof infringement or misappropriation of the intellectual propertyrights of others; the continued availability of supplies fromsingle-source suppliers and manufacturers of our key laser components;the ability of our managers, operations and facilities to manage ourgrowth; the success of our expansion into markets outside the UnitedStates; whether we lose any of our key executives or fail to attractqualified personnel; or if our new products or applications fail tobecome commercially viable.

Certain of these risks and uncertainties, in addition to otherrisks, are more fully described in the company's annual report on form10-K for the period ending December 31, 2004, as filed with theSecurities and Exchange Commission on March 29, 2005.

These forward-looking statements are made only as of the date ofthis press release, and the company assumes no obligation to update orrevise the forward-looking statements, whether as a result of newinformation, future events or otherwise.